Hangzhou Hongsai Biotechnology

Hangzhou Hongsai Biotechnology is a clinical-stage biotechnology company headquartered in Hangzhou, China, dedicated to the development of innovative cell-based immunotherapies. The company's core expertise lies in the large-scale expansion and activation of Natural Killer (NK) cells and Cytokine-Induced Killer (CIK) cells for oncology applications. Hongsai Biotech operates a state-of-the-art GMP-compliant facility that supports both its internal R&D pipeline and its commercial cell storage services. Their therapeutic focus primarily targets solid tumors and hematological malignancies through advanced cellular engineering. By integrating cell preservation with therapeutic development, the company provides a comprehensive ecosystem for immune health and cancer treatment.